Literature DB >> 20659815

Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis.

Christian Krarup1.   

Abstract

OBJECTIVE: The diagnosis of amyotrophic lateral sclerosis (ALS) includes demonstration of lower motor neuron (LMN) and upper motor neuron (UMN) involvement of bulbar and spinal muscles. Electromyography (EMG) is essential to confirm LMN affection in weak muscles, and to demonstrate changes in clinically non-involved muscles. The aim of the study was to determine the relative importance of ongoing (active) denervation, fasciculations, chronic partial denervation with reinnervation at weak effort and loss of motor units at maximal voluntary contraction (MVC) in ALS.
METHODS: EMG was carried out in weak and non-weak muscles in 220 patients suspected of ALS using concentric needle electrodes. Denervation activity and fasciculations in 966 muscles was quantified, the mean durations and amplitudes of motor unit potentials (MUPs) were compared to controls in 745 muscles, and the amplitudes and recruitment patterns at maximal voluntary effort were measured in 939 muscles. Twenty-five percent of patients had clinical involvement of 1 region, 42% of 2 regions and 33% of 3 regions. Clinically 65% had UMN involvement. Eighty-six percent of the patients had died on follow-up.
RESULTS: Denervation activity occurred in 72% of weak muscles but in only 45% of non-weak muscles. Fasciculations occurred in 56% of weak muscles and in 65% of non-weak muscles. MUPs showed reinnervation in 87-91% of weak and non-weak muscles and in 44% of muscles neurogenic MUPs occurred in the absence of denervation activity. In patients with clinical involvement of 1 region, combined EMG criteria increased the number of affected regions in 93%, and in 40% of patients with clinical involvement of 2 regions EMG increased the number of involved regions.
CONCLUSIONS: Quantitative EMG confirmed widespread LMN involvement in patients with early ALS including clinically non-involved regions. These findings suggest that the maintenance of force is due to compensatory reinnervation in early disease and that this capacity may decline at later stages of ALS. SIGNIFICANCE: These findings support a recent consensus report (the Awaji criteria) that EMG should have equivalent weight to clinical manifestations to indicate LMN involvement. The findings strongly indicate that spontaneous activity is insufficient to show LMN involvement in non-affected muscles at early stages of disease, and that analysis of MUPs are needed to document the distribution of LMN involvement. Copyright Â
© 2010 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20659815     DOI: 10.1016/j.clinph.2010.06.027

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  17 in total

1.  Techniques and applications of EMG: measuring motor units from structure to function.

Authors:  Rachel C Thornton; Andrew W Michell
Journal:  J Neurol       Date:  2012-01-25       Impact factor: 4.849

2.  Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.

Authors:  Samir Abu-Rumeileh; Veria Vacchiano; Corrado Zenesini; Barbara Polischi; Silvia de Pasqua; Enrico Fileccia; Angela Mammana; Vitantonio Di Stasi; Sabina Capellari; Fabrizio Salvi; Rocco Liguori; Piero Parchi
Journal:  J Neurol       Date:  2020-02-25       Impact factor: 4.849

3.  Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis.

Authors:  Eleonora Colombo; Alberto Doretti; Francesco Scheveger; Alessio Maranzano; Giulia Pata; Delia Gagliardi; Megi Meneri; Stefano Messina; Federico Verde; Claudia Morelli; Stefania Corti; Luca Maderna; Vincenzo Silani; Nicola Ticozzi
Journal:  J Neurol       Date:  2022-10-02       Impact factor: 6.682

4.  Quantitative analysis of the features of fasciculation potentials and their relation with muscle strength in amyotrophic lateral sclerosis.

Authors:  Kota Bokuda; Toshio Shimizu; Hideki Kimura; Toshihiro Yamazaki; Tsutomu Kamiyama; Kazuhiko Watabe; Akihiro Kawata; Masaharu Hayashi; Eiji Isozaki
Journal:  Neurol Sci       Date:  2016-08-19       Impact factor: 3.307

5.  The puzzling case of hyperexcitability in amyotrophic lateral sclerosis.

Authors:  Jong Seok Bae; Neil G Simon; Parvathi Menon; Steve Vucic; Matthew C Kiernan
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

6.  Endomicroscopy and electromyography of neuromuscular junctions in situ.

Authors:  Rosalind Brown; Kosala N Dissanayake; Paul A Skehel; Richard R Ribchester
Journal:  Ann Clin Transl Neurol       Date:  2014-10-10       Impact factor: 4.511

7.  The Awaji criteria increases the diagnostic sensitivity of the revised El Escorial criteria for amyotrophic lateral sclerosis diagnosis in a Chinese population.

Authors:  Da-Wei Li; Mingsheng Liu; Bo Cui; Jia Fang; Yu-Zhou Guan; Qingyun Ding; Xiaoguang Li; Liying Cui
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

8.  Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity.

Authors:  Uros Klickovic; Luca Zampedri; Christopher D J Sinclair; Stephen J Wastling; Karin Trimmel; Robin S Howard; Andrea Malaspina; Nikhil Sharma; Katie Sidle; Ahmed Emira; Sachit Shah; Tarek A Yousry; Michael G Hanna; Linda Greensmith; Jasper M Morrow; John S Thornton; Pietro Fratta
Journal:  Neurology       Date:  2019-08-07       Impact factor: 9.910

Review 9.  Quantifying disease progression in amyotrophic lateral sclerosis.

Authors:  Neil G Simon; Martin R Turner; Steve Vucic; Ammar Al-Chalabi; Jeremy Shefner; Catherine Lomen-Hoerth; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2014-09-30       Impact factor: 10.422

10.  The evolving role of surface electromyography in amyotrophic lateral sclerosis: A systematic review.

Authors:  J Bashford; K Mills; C Shaw
Journal:  Clin Neurophysiol       Date:  2019-12-27       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.